Top

Published in:

Open Access 01-12-2023 | Thrombocytopenia | Case report

Sinopharm (HB02)-associated vaccine-induced immune thrombotic thrombocytopenia: a case report

Authors: Mohammad Sistanizad, Tahereh Sabaghian, Hossein Amini, Fahimeh Hadavand, Mahmood Nabavi, Mehran Kouchek, Mir Mohammad Miri, Sara Salarian, Seyedpouzhia Shojaei, Omid Moradi

Published in: Journal of Medical Case Reports | Issue 1/2023

Abstract

Background

Vaccine-induced thrombotic thrombocytopenia is associated with the coronavirus disease 2019 vaccines. It has been reported by vector-based vaccines. To the best of our knowledge, there is no report about vaccine-induced thrombotic thrombocytopenia in whole-virus vaccines. We are presenting the first case of vaccine-induced thrombotic thrombocytopenia with this type of vaccine.

Case presentation

An 18-year-old male Caucasian patient with complaints of severe abdominal, low back, and lower extremity pain presented to the medical center. He received the first dose of the Sinopharm (HB02) vaccine against coronavirus disease 2019 10 days before hospital attendance. In the laboratory examination, decreased platelet count and increased D-dimer were observed. During hospital admission, the diagnosis of pulmonary embolism was reached. He received vaccine-induced thrombotic thrombocytopenia therapy consisting of intravenous immune globulin and direct oral anticoagulant. Platelet count increased and he was discharged after 1 month.

Conclusion

This case highlights the possibility of vaccine-induced thrombotic thrombocytopenia occurrence by whole-virus coronavirus disease 2019 vaccines. Compared with vector-based vaccines, this phenomenon is rare for whole-virus vaccines. More studies on this type of vaccine regarding thrombotic thrombocytopenia should be considered.

Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science. 2020;370(6518):763–5. https://doi.org/10.1126/science.abe5938.CrossRefPubMed

Laine C, Cotton D, Moyer DV. COVID-19 vaccine: what physicians need to know. Ann Intern Med. 2020;173(10):830. https://doi.org/10.7326/M20-6841.CrossRefPubMed

Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–60. https://doi.org/10.1001/jama.2020.15543.CrossRefPubMed

Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. https://doi.org/10.1016/S1473-3099(20)30831-8.CrossRefPubMed

Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–30. https://doi.org/10.1056/NEJMoa2104882.CrossRefPubMed

Reinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–101. https://doi.org/10.1056/NEJMoa2104840.CrossRef

Bussel J, Connors J, Cines D. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia. Version 1.2. American Society of Hematology April 25, 2021. Available from: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia.

Nazy I, Sachs UJ, Arnold DM, et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021;19(6):1585–8. https://doi.org/10.1111/jth.15341.CrossRefPubMed

Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534–7. https://doi.org/10.1002/ajh.26132.CrossRefPubMedPubMedCentral

10.

Greinacher A, Schönborn L, Siegerist F, Steil L, Palankar R, Handtke S, Reder A, Thiele T, Aurich K, Methling K, Lalk M, Völker U, Endlich N. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol. 2022;59(2):97–107. https://doi.org/10.1053/j.seminhematol.2022.02.004.CrossRefPubMedPubMedCentral

11.

Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385(18):1680–9. https://doi.org/10.1056/NEJMoa2109908.CrossRefPubMed

Title: Sinopharm (HB02)-associated vaccine-induced immune thrombotic thrombocytopenia: a case report
Authors: Mohammad Sistanizad
Tahereh Sabaghian
Hossein Amini
Fahimeh Hadavand
Mahmood Nabavi
Mehran Kouchek
Mir Mohammad Miri
Sara Salarian
Seyedpouzhia Shojaei
Omid Moradi
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Thrombocytopenia
COVID-19
Thrombosis
Published in: Journal of Medical Case Reports / Issue 1/2023
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/s13256-023-04086-7

At a glance: The STEP trials

Springer Medicine

Sinopharm (HB02)-associated vaccine-induced immune thrombotic thrombocytopenia: a case report

Abstract

Background

Case presentation

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Salmonella meningitis in a young child from Pakistan: a case report

Localized amyloidosis of the ureter: a case report

Transhepatic ultrasound guided embolization as a successful novel technique in treatment of pediatric complex intrahepatic arterioportal fistula: a case report and review of the literature

Management of traumatic cervical epidural hematoma in patients on Xa-inhibitors: a case report and review of the literature

A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report

Neonatal PPH due to methylmalonic acidemia